Drug-eluting stents: A reappraisal

Heart

Volumn 96, Issue 7, 2010, Pages 489-493

  Garg, Scot ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BARE METAL STENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EDITORIAL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; STENT THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FORECASTING; GRAFT OCCLUSION, VASCULAR; HUMANS; PROSTHESIS FAILURE;

EID: 77950584672     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.189522     Document Type: Editorial

References (72)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780
2. Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008;148:234-238 (Pubitemid 351665508)
3. Ludman P. BCIS Audit Returns Adult Interventional Procedures Jan 2008-Dec 2008. http://www.bcis. org.uk/resources/audit/audit2008 (accessed 15 Nov 2009).
4. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 2007;115:1433-9; discussion 9.
5. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937e48.
6. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997 (Pubitemid 46376799)
7. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008. (Pubitemid 46376800)
8. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007;356:1030-1039 (Pubitemid 46376803)
9. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029 (Pubitemid 46376802)
10. Weisz G, Leon MB, Holmes DRJr., et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009;53:1488-1497
11. Silber S, Colombo A, Banning AP, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderaterelease polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009;120:1498-1504
12. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195
13. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009;119:3198-3206
14. De Labriolle A, Bonello L, Lemesle G, et al. Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents. Arch Cardiovasc Dis 2009;102:209-217
15. Bainey KR, Norris CM, Graham MM, et al. Clinical in-stent restenosis with bare metal stents: is it truly a benign phenomenon? Int J Cardiol 2008;128:378-382
16. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-1264
17. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998;98:224-233 (Pubitemid 28337613)
18. Moreno PR, Palacios IF, Leon MN, et al. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 1999;84:462-6, A9.
19. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402 (Pubitemid 47541971)
20. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-2398 (Pubitemid 350145074)
21. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55; discussion 55. (Pubitemid 46648381)
22. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784-2814 (Pubitemid 44871464)
23. Lagerqvist B, James SK, Stenestrand U, et al. Longterm outcomes with drug-eluting stents versus baremetal stents in Sweden. N Engl J Med 2007; 356:1009-1019 (Pubitemid 46376801)
24. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591 (Pubitemid 44881238)
25. Serruys PW, Daemen J. The SCAAR registry or the Swedish yo-yo. EuroIntervention 2007;3:297e300.
26. James SK, Stenestrand U, Lindback J, et al. Longterm safety and efficacy of drug-eluting versus baremetal stents in Sweden. N Engl J Med 2009;360:1933-1945
27. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009 (Pubitemid 46740352)
28. Farb A, Boam AB. Stent thrombosis reduxethe FDA perspective. N Engl J Med 2007;356:984-987 (Pubitemid 46376798)
29. Brodie BR, Stuckey T, Downey W, et al. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv 2008;1:405-414
30. Lasala JM, Cox DA, Lewis SJ, et al. Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention 2009;5:67e77.
31. Applegate RJ, Sacrinty MT, Kutcher MA, et al. "Offlabel" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2008;51:607e14.
32. Ko DT, Chiu M, Guo H, et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol 2009;53:1773-1782
33. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a selfexpanding coronary-artery stent. N Engl J Med 1991;324:13-17.
34. Barragan P, Sainsous J, Silvestri M, et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn 1994;32:133-138 (Pubitemid 24184667)
35. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronaryartery stents. N Engl J Med 1996;334:1084-1089 (Pubitemid 26120185)
36. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98:1597e603.
37. Morice MC, Zemour G, Benveniste E, et al. Intracoronary stenting without coumadin: one month results of a French multicenter study. Cathet Cardiovasc Diagn 1995;35:1-7.
38. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688
39. Onuma Y. Incidence of late stent thrombosis up to 5 years after implantation of drug eluting stents in clinical practice. Presentation European Society of Cardiology meeting, Barcelona. 31 8 2009.
40. Serruys P, Onuma Y, Garg S, et al. Five-year clinical outcomes of the arterial revascularisation therapies (ARTS-II) study of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol In press.
41. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48: 193-202. (Pubitemid 43929240)
42. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-1510 (Pubitemid 46986103)
43. Wijns W. Late stent thrombosis after drug-eluting stent: seeing is understanding. Circulation 2009;120:364-365
44. Garg S, Serruys P. A review of the benefits of and safety concerns associated with drug eluting coronary stents. Expert Rev Cardiovasc Ther. In press.
45. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007;115:2842-2847 (Pubitemid 46869671)
46. Daemen J, Simoons ML, Wijns W, et al. ESC forum on drug eluting stents European heart house, Nice, 27e28 September 2007. Eur Heart J 2009;30:152-161
47. Singh M, Rihal CS, Gersh BJ, et al. Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary intervention: a single-institution experience. Circulation 2007;115:2835-2841 (Pubitemid 46869670)
48. Kappetein AP, Dawkins KD, Mohr FW, et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg 2006;29:486-491
49. Kappetein AP. Optimal revascularization strategy in patients with three-vessel disease and/or left main disease. The 2-year Outcomes of the SYNTAX Trial. In: Presentation at the ESC Congress, Barcelona, 2 9 2009. http://www.syntaxscore.com. (accessed Nov 2009).
50. Morice MC. Multivessel disease lessons from SYNTAX (early results and 2 year follow-up): interventional perspectives. Presentation at Transcatheter Therapeutics, San Francisco, 21 9 2009.
51. Serruys PW. Left main lessons from SYNTAX (early results and 2 year follow-up): interventional perspectives. In: Presentation Transcatheter Therapeutics, 21 9 2009. http://www.tctmd.com/ txshow.aspx?tid=9390768&id= 83938&trid=938634. (accessed Nov 2009).
52. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010;55:432-440
53. Banning A, Westaby S, Morice MC, et al. Comparison of cardiac surgery and paclitaxel-eluting stents in nondiabetic and diabetic patients with left main and/or 3-vessel coronary artery disease. J Am Coll Cardiol. In press.
54. Beatt K. DES vs. surgery in diabetics: insights from CARDIA, SYNTAX, and beyond. Presentation at Transcatheter Therapeutics, San Francisco, 21 9 2009.
55. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of multivessel disease (FREEDOM) Trial. Am Heart J 2008; 155:215-223
56. Smits P. COMPARE Trial. Presentation at Transcatheter Therapeutics San Francisco, 23 9 2009.
57. Garg S, Serruys PW, Onuma Y, et al. Three year clinical follow up of the XIENCE V Everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. The SPIRIT II Trial. J Am Coll Cardiol Intv 2009;2:1190-1198
58. Stone GW. The XIENCE VdPROMUS Everolimus- Eluting Stent: comprehensive update of the Clinical Trial Program. Presentation at Transcatheter Therapeutics, 21 9 2009. http://www.tctmd.com/ txshow.aspx?tid=939082&id= 84006&trid=938634. (accessed 28 Oct 2009).
59. Hamm C. 5 years later and more than 20,000 patients studied: the ENDEAVOR clinical programme. EuroPCR 19the22nd May 2009; Barcelona [online]. http:// www.europcronline.com/fo/lecture/view-slide.php? idCongres=5&id=7617 (accessed 20 Jun 2009).
60. Garg S, Sarno G, Serruys PW, et al. The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. Eurointervention. In press.
61. Klauss V. LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer. Presentation Transcatheter Therapeutics, San Francisco, 22 9 2009.
62. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-279 (Pubitemid 43754385)
63. Ruef J, Storger H, Schwarz F, et al. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv 2008;71:333-339 (Pubitemid 351428151)
64. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-299
65. Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V Everolimus-eluting stent in the treatment of patients with De Novo native coronary artery lesions: The SPIRIT II Trial. Circ Cardiovasc Interv 2009;2:339-347
66. Raber L. SIRTAX-LATE: five-year clinical and angiographic follow-up from a prospective randomized trial of Sirolimus-Eluting and Paclitaxel-Eluting stents Presentation Transcatheter Therapeutics, San Francisco, 22 9 2009.
67. Aoki J, Abizaid AC, Ong AT, et al. Serial assessment of tissue growth inside and outside the stent after implantation of drug-eluting stent in clinical trials. Does delayed neointimal growth exist? EuroIntervention 2005;1:235-255
68. Grube E. Biofreedom: polymer-free drug-eluting stentdpreclinical results and first-in-man trial status. EuroPCR 19th-22nd May 2009; Barcelona [online]. http://www.europcronline.com/fo/lecture/view-slide.php? idCongres=5&;id=7642 (accessed 10 Jun 2009).
69. Costa JR Jr, Abizaid A, Costa R, et al. 1-year results of the hydroxyapatite polymer-free Sirolimus-Eluting stent for the treatment of single De Novo Coronary Lesions: the VESTASYNC I Trial. J Am Coll Cardiol Intv 2009;2:422-427
70. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102:399-404. (Pubitemid 30490677)
71. Onuma Y, Serruys PW, The Absorb Investigators. Abstract 4400: ABSORB Trial: three year clinical results of the evaluation of the Bioabsorbable Everolimus-Eluting Coronary Stent System in the treatment of patients with de novo native coronary artery lesions. Circulation 2009;120:S951.
72. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.